BioStock: Cereno Scientific raises 95.3 million SEK
The recent IND FDA acceptance to initiate its phase II trial with CS1 in pulmonary arterial hypertension patients was a key milestone for Cereno Scientific. Last week, the company announced it was able to raise more than 95 MSEK through a TO1 warrant exercise, which gives the company even more assurance in the pursuit of its vision to develop better treatments for common and rare cardiovascular diseases.
Read the article at biostock.se:
https://www.biostock.se/en/2021/10/cereno-scientific-raises-95-3-million-sek/
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se